Regeneron Initiates its First Clinical Study of Antibody Cocktail for the Treatment and Prevention of COVID-19

 Regeneron Initiates its First Clinical Study of Antibody Cocktail for the Treatment and Prevention of COVID-19

Regeneron Initiates its First Clinical Study of Antibody Cocktail for the Treatment and Prevention of COVID-19

Shots:

  • The company has reported the initiation of the first clinical trial of REGN-COV2. The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people that are at high risk of exposure and uninfected people with close exposure to a COVID-19 patient
  • The first two adaptive P-I/II/III studies are evaluating REGN-COV2 (REGN10933+REGN10987) as a treatment for hospitalized & non-hospitalized patients with COVID-19. The P-I & P-II portion will focus on virologic and safety endpoints & clinical endpoints respectively
  • Data from the P-I/II studies will be used to refine the EPs and will determine the size for P-III studies while BARDA has funded the REGN-COV2’s preclinical development and pre/clinical manufacturing. Additionally, Regeneron has developed REGN-EB3, a novel triple antibody treatment for Ebola which is under FDA’s regulatory review

Click here to read full press release/ article | Ref: Regeneron | Image: Regeneron

Related News: Regeneron to Initiate COVID-19 Antibody Program in Early Summer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post